CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionOperating margin is -87.9%, lower than 95% of its Medical Devices peers (median 8.1%)
- FinancialsAltman Z-Score 10.11: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
770.47MUSDvs all stocks (USD)
Revenue (TTM)
110.24MUSDvs all stocks (USD)
Profit Margin
-60.27%vs Medical Devices peers
52-Week Change
20.91%vs all stocks
Market Capitalization
770.47MUSDvs all stocks (USD)
Enterprise Value
558.70MUSDvs all stocks (USD)
Forward P/E
-7.07xvs Medical Devices peers
Price to Sales (TTM)
6.83xvs Medical Devices peers
Price to Book (MRQ)
2.78xvs Medical Devices peers
Enterprise to Revenue
5.07xvs Medical Devices peers
Enterprise to EBITDA
-7.40xvs Medical Devices peers
Gross Margin
59.50%vs Medical Devices peers
Profit Margin
-60.27%vs Medical Devices peers
Operating Margin
-87.86%vs Medical Devices peers
Return on Assets (TTM)
-15.04%vs Medical Devices peers
Return on Equity (TTM)
-22.71%vs Medical Devices peers
Revenue (TTM)
110.24MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.51USDUpdated Jul 18, 2026Quarterly Revenue Growth
56.60%vs Medical Devices peers
Gross Profit (TTM)
63.00MUSDvs all stocks (USD)
EBITDA (TTM)
-75.45MUSDvs all stocks (USD)
Net Income (TTM)
-66.44MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
56.62%vs Medical Devices peers
Operating Cash Flow (TTM)
-54.78MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-44.06MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
100.25MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
44.71MUSDFY2025 · Dec 31, 2025Gross Profit
55.54MUSDFY2025 · Dec 31, 2025Operating Income
-71.68MUSDvs all stocks (USD)
Pre-tax Income
-73.20MUSDFY2025 · Dec 31, 2025Net Income
-73.20MUSDFY2025 · Dec 31, 2025EBIT
-71.68MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-56.36MUSDFY2025 · Dec 31, 2025Research & Development
34.79MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
92.43MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.93MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.81USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.81USDFY2025 · Dec 31, 2025Basic Shares Outstanding
40.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
40.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-73.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-66.54MUSDFY2025 · Dec 31, 2025Free Cash Flow
-71.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
31.68MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-73.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.88MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.38MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.99MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-5.16MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.54MUSDFY2025 · Dec 31, 2025Capital Expenditures
-5.30MUSDFY2025 · Dec 31, 2025Purchase of Investments
-327.51MUSDFY2025 · Dec 31, 2025Sale of Investments
170.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-162.81MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
210.12MUSDFY2025 · Dec 31, 2025Shares Outstanding
44.56MSharesUpdated Jul 18, 2026Float Shares
25.35MSharesUpdated Jul 18, 2026Shares Short
6.82MSharesUpdated Jul 18, 2026Short Ratio
6.14daysvs all stocks
Short % of Shares Outstanding
15.38%vs all stocks
% Held by Insiders
1.09%vs all stocks
% Held by Institutions
111.67%vs all stocks
Total Cash (MRQ)
199.52MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.48USDUpdated Jul 18, 2026Total Debt (MRQ)
6.91MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0255xvs Medical Devices peers
Current Ratio (MRQ)
10.69xvs Medical Devices peers
Book Value per Share (MRQ)
6.09USDUpdated Jul 18, 2026Total Assets
328.74MUSDvs all stocks (USD)
Total Current Assets
267.90MUSDFY2025 · Dec 31, 2025Total Liabilities
41.13MUSDFY2025 · Dec 31, 2025Total Non-current Assets
60.84MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
10.21MUSDFY2025 · Dec 31, 2025Total Current Liabilities
30.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
31.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
187.55MUSDFY2025 · Dec 31, 2025Accounts Receivable
17.12MUSDFY2025 · Dec 31, 2025Inventory
21.72MUSDFY2025 · Dec 31, 2025Accounts Payable
5.00MUSDFY2025 · Dec 31, 2025Short-term Debt
1.94MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.56MUSDFY2025 · Dec 31, 2025Other Current Liabilities
328.00KUSDFY2025 · Dec 31, 2025Long-term Debt
5.37MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.55MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-369.94MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
287.61MUSDvs all stocks (USD)
52-Week Low
8.80USDUpdated Jul 18, 202652-Week High
32.71USDUpdated Jul 18, 202652-Week Change
20.91%vs all stocks
50-Day MA
13.30USDUpdated Jul 18, 2026200-Day MA
17.88USDUpdated Jul 18, 2026Avg 10-Day Volume
841.74KSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.03MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.37USDUpdated Jul 18, 2026Other Income / Expense
-12.45MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -87.9%, lower than 95% of its Medical Devices peers (median 8.1%)Significant
Operating margin: -0.88Industry median: 0.08Industry P5: -0.73Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.59Profit Margin: -0.60
Financial Health
Altman Z-Score 10.11: safe zoneNotable
Altman Z-Score: 10.11
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Si-Bone Inc.
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Trump Media & Technology Group Corp.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Nusantara Sawit Sejahtera Tbk
1 interpretationPartial Recovery After Sharp Decline
Enovix Corporation
2 interpretationsPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC